Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration

Author:

Spring Laura M.123ORCID,Mortensen Lindsey1ORCID,Abraham Elizabeth1,Keenan Jennifer1,Medford Arielle12ORCID,Ma Annie1ORCID,Padden Sarah1,Denault Elyssa1ORCID,Ryan Lianne1,Iafrate A. John12,Lennerz Jochen12ORCID,Hochberg Ephraim12ORCID,Wander Seth A.124ORCID,Moy Beverly123ORCID,Isakoff Steven J.12ORCID,Juric Dejan12ORCID,Brennan Kimberly A.5,Smith Deborah E.6,Civiello Barbara7,Mulvey Therese12ORCID,Comander Amy1238ORCID,Ellisen Leif W.12ORCID,Schwartz Joel H.146,Bardia Aditya123ORCID

Affiliation:

1. Massachusetts General Hospital, Boston, MA

2. Harvard Medical School, Boston, MA

3. Mass General Cancer Center at Waltham, Waltham, MA

4. Mass General/North Shore Cancer Center, Danvers, MA

5. Mass General Cancer Center at Emerson Hospital, Concord, MA

6. Mass General Cancer Center at Cooley Dickinson Hospital, Northampton, MA

7. Mass General Cancer Center at Wentworth-Douglass Hospital, Dover, NH

8. Mass General Cancer Center at Newton Wellesley Hospital, Newton, MA

Abstract

PURPOSE There is a demand for improved care delivery surrounding genomic testing and clinical trial enrollment among patients with metastatic breast cancer (MBC). We sought to improve the current process via real-time informal consultation and prescreening assessment for patients with MBC treated by community and academic medical oncologists by implementing a virtual molecular and precision medicine (vMAP) clinic. METHODS The vMAP program used a virtual referral system directed to a multidisciplinary team with precision medicine expertise. Providers contacted vMAP regarding patients with MBC, and on receipt of referral, the vMAP team engaged in discussion to identify if further diagnostics were needed (including genomic testing) and to identify potential clinical trials or standard treatment options. Recommendations were then sent to the referring provider within 72 hours. Pre-/postsurveys were issued to network physicians to assess for barriers, clinical trial access, and vMAP referral experience. Program implementation was evaluated with the Squire 2.0 reporting guidelines for quality improvement in health care as a framework. RESULTS Eighty-one cases from 22 providers were referred to vMAP over a 26-month period. The average response time to the referring provider with a finalized recommendation was 1.90 ± 1.82 days. A total of 86.4% of cases had clinical trial options on vMAP prescreen, with 40.7% initiating formal screening assessments and 27 patients (33.3%) ultimately enrolling on trials. On resurvey, 92% of survey responses across community oncology referring providers said that they were very likely to use vMAP again. CONCLUSION In the initial 2-year period, vMAP demonstrated an efficient means to offer real-time interpretation of genomic testing and identification of clinical trials for patients with MBC, with effective clinical trial enrollment and high rates of referring provider satisfaction.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology (nursing),Health Policy,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3